Press Releases

Press Releases
Date Title and Summary View
06/13/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel E-selectin antagonist GMI-1271 for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and eld...
06/10/2016 Data presented via poster at European Hematology Association 21st Congress ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced data from the Phase 1 portion of its Phase 1/2 clinical trial of its novel E-selectin antagonist, GMI-1271, combined with i...
06/06/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced dosing of the first patient with relapsed/refractory acute myeloid leukemia in the Phase 2 portion of its ongoing Phase 1/2 clinical trial evaluating its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy....
06/02/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Financial Officer Brian Hahn will provide a company overview at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 9:30 a.m. EDT in New York City. To access the live webcast ...
05/25/2016 GMI-1271 Inhibits Breast Cancer Cell Homing to the Bone Marrow ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the peer-reviewed journal, Science Translational Medicine, has published preclinical research in its May 25 issue pointing ...
05/19/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that initial efficacy data from a Phase 1/2 clinical trial on the effects of drug candidate GMI-1271 combined with chemotherapy on patients with acute myeloid leukemia (AML) were accepted as a poster to be presented at the Europe...
05/04/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the first quarter ended March 31, 2016. "In February of 2016, we announced the topline readout of data from the first two cohorts in our ongoing Phase 1/2 clinical trial evaluating our ...
04/25/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that collaborative research on the effects of its clinical drug candidate GMI-1271 on E-selectin, and acetaminophen- induced liver damage was accepted for an oral presentation at "Digestive Disease Week," the annual meet...
03/21/2016 GAITHERSBURG, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Daniel Junius to its Board of Directors. Mr. Junius is President and Chief Executive Officer and a member of the board of directors of ImmunoGen, Inc., an industry leader in the field of antibody drug ...
03/17/2016 Data bolsters scientific rationale for clinical evaluation of GMI-1359 in AML patients harboring aberrant FLT3 and in patients with pancreatic cancer GAITHERSBURG, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that pre-clinical research demonstrating the p...
FirstPrevious
3
... NextLast
Add to Briefcase = add release to Briefcase